Alzheimer`s disease (AD) is characterised neuropathologically by the presence of extracellular amyloid plaques, intraneuronal neurofibrillary tangles, and cerebral neuronal loss. The pathological changes in AD are believed to start even decades before clinical symptoms are detectable. AD gradually affects episodic memory, cognition, behaviour and the ability to perform everyday activities. Mild cognitive impairment (MCI) represents a transitional state between normal aging and dementia disorders, especially AD. The predictive accuracy of the current and commonly used MCI criteria devide this disorder into amnestic (aMCI) and non-amnestic (naMCI) MCI. It seems that many individuals with aMCI tend to convert to AD. However many MCI individual...
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase o...
The field of aging and dementia research is advancing rapidly toward the stage of earlier identifica...
The aim of this study is to support the use of biomarkers in the diagnosis of mild cognitive impairm...
peer reviewedPURPOSE: To know whether mild cognitive impairment (MCI) patients will develop Alzheime...
Background: Ongoing research is focusing on the identification of those individuals with mild cogniti...
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase o...
Background: Diagnosis of Alzheimer's disease (AD) confirmed by biomarkers allows the patient to make...
To test the validity of the new diagnostic criteria for Alzheimer’s disease (AD) in a naturalistic s...
Introduction Mild cognitive impairment (MCI) is defined as abnormal cognitive state, but does not me...
Mild cognitive impairment (MCI) is a syndrome defined as cognitive decline, but not sufficient to me...
BACKGROUND: Mild cognitive impairment (MCI) is a heterogeneous clinical entity that comprises the pr...
Patients with amnestic mild cognitive impairment (aMCI) may progress to clinical Alzheimer disease (...
Predicting the conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) and of th...
Using the database of the Alzheimer's Disease Neuroimaging Initiative, we examined the value of neur...
Importance: Patients with amnestic mild cognitive impairment (aMCI) may progress to clinical Alzheim...
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase o...
The field of aging and dementia research is advancing rapidly toward the stage of earlier identifica...
The aim of this study is to support the use of biomarkers in the diagnosis of mild cognitive impairm...
peer reviewedPURPOSE: To know whether mild cognitive impairment (MCI) patients will develop Alzheime...
Background: Ongoing research is focusing on the identification of those individuals with mild cogniti...
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase o...
Background: Diagnosis of Alzheimer's disease (AD) confirmed by biomarkers allows the patient to make...
To test the validity of the new diagnostic criteria for Alzheimer’s disease (AD) in a naturalistic s...
Introduction Mild cognitive impairment (MCI) is defined as abnormal cognitive state, but does not me...
Mild cognitive impairment (MCI) is a syndrome defined as cognitive decline, but not sufficient to me...
BACKGROUND: Mild cognitive impairment (MCI) is a heterogeneous clinical entity that comprises the pr...
Patients with amnestic mild cognitive impairment (aMCI) may progress to clinical Alzheimer disease (...
Predicting the conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) and of th...
Using the database of the Alzheimer's Disease Neuroimaging Initiative, we examined the value of neur...
Importance: Patients with amnestic mild cognitive impairment (aMCI) may progress to clinical Alzheim...
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase o...
The field of aging and dementia research is advancing rapidly toward the stage of earlier identifica...
The aim of this study is to support the use of biomarkers in the diagnosis of mild cognitive impairm...